Wednesday, December 18, 2024

FDA Grants Key Designation for RP Therapy

EyeDNA’s investigational gene therapy receives the Rare Pediatric Disease designation as a potential treatment for retinitis pigmentosa.

Wednesday, December 18, 2024

Eylea HD Phase 3 Trial Confirms Extended Dosing Efficacy for RVO

The QUASAR trial demonstrates noninferiority in treating macular edema secondary to retinal vein occlusion, with longer intervals between treatments. Regeneron will seek FDA approval in 2025.

Wednesday, December 18, 2024

ViGeneron Receives FDA Clearance for Gene Therapy

The German company’s VG801 gene therapy targets Stargardt disease and ABCA4-linked retinal conditions.

Monday, December 16, 2024

Peter K. Kaiser, MD, Welcomes Diana V. Do, MD, as the New Editor in Chief of Retinal Physician

Thursday, December 12, 2024

Retinal Physician Welcomes Diana V. Do, MD, as New Editor in Chief

Dr. Do, vice chair of clinical affairs and professor of ophthalmology at the Byers Eye Institute, succeeds Peter K. Kaiser, MD, as editor in chief of the magazine.

Friday, December 6, 2024

EyePoint Initiates LUCIA Trial

The phase 3 trial will evaluate the safety and efficacy of the company’s Duravyu intraocular insert in patients with wet AMD.

Friday, December 6, 2024

Avant Technologies, Ainnova Partner on Device

The company says the AI-powered fundus camera will be available in the United States and Europe.

Friday, December 6, 2024

Ocular Therapeutix Completes Enrollment in Implant Trial

The phase 3 trial SOL-1 will evaluate the safety and efficacy of the Axpaxli intravitreal implant as a treatment for wet AMD.

Friday, December 6, 2024

Roche, Ainnova Partner on Vision Screening Program

A pilot program in Costa Rica prioritizes early detection and treatment of diabetic retinopathy.

Thursday, December 5, 2024

Scott Hunter, chief commercial officer of Neurotech, dies

Wednesday, November 20, 2024

Cencora to Acquire Retina Consultants of America

The $4.6 billion deal expands the drug wholesaler’s reach in retinal care.

Tuesday, November 19, 2024

Ocugen Reports Preliminary Data from Gene Therapy Trial

Six-month results from the ArMaDa trial for OCU410, a 1-time therapy delivered via subretinal injection, demonstrated safety and functional vision benefits for GA patients.

Monday, November 18, 2024

Adverum’s Ixo-vec Shows Durable Benefit in nAMD Trials

Data from the LUNA trial, as well as the OPTIC extension study, show a reduction in anti-VEGF injections along with a favorable safety profile. The company is planning a phase 3 trial for 2025.

Tuesday, November 12, 2024

EyePoint Initiates Phase 3 Trial for Duravyu

The first patients have been dosed in the LUGANO trial for wet AMD. The company expects to initiate the LUCIA trial by year-end.

Tuesday, November 12, 2024

FDA Extends Review Period for MacTel Therapy

The PDUFA date for Neurotech Pharmaceuticals's NT-501 has been pushed to March 2025.

Tuesday, November 12, 2024

AlloVir, Kalaris Announce Plans to Merge

The combined company will focus on the development of TH103, an intravitreal treatment being studied for age-related macular degeneration.

Tuesday, November 12, 2024

Iron-modulating Therapy Targets Geographic Atrophy

PulseSight Therapeutics presented positive preclinical results on its transferrin therapy at a European meeting.

Tuesday, November 5, 2024

FDA Accelerates Review of ROP Treatment

Japanese drugmaker reports plans to conduct a phase1b/2 study of FLQ-101, a preventative treatment for retinopathy of prematurity, in early 2025.

Tuesday, November 5, 2024

FDA Approves Valeda Light Delivery System for Dry AMD Treatment

Data from the LIGHTSITE III trial confirmed the safety and efficacy of LumiThera's photobiomodulation device as a treatment for vision loss due to age-related macular degeneration. 

Friday, November 1, 2024

Duravyu Shows Positive Interim Results in DME Trial

Data from the phase 2 VERONA trial show improvement in BCVA and CST over baseline.

Wednesday, October 23, 2024

Retina Implant Restores Vision in European Trial

Patients with late stage dry age-related macular degeneration regained the ability to read and recognize faces after receiving the PRIMA retinal implant. 

Wednesday, October 23, 2024

Study Highlights Waste of Eye Drops

Research presented at AAO shows clinics discard most eye drops long before expiration.

Wednesday, October 23, 2024

Ocuphire Pharma Acquires Opus Genetics

The new combined company will focus on gene therapy treatments for inherited retinal diseases.

Friday, October 11, 2024

Nanoscope to Seek Biologics License for RP Treatment

Following FDA feedback, the company reported that it will submit a BLA in early 2025 for its multicharacteristic opsin MCO-010.

Wednesday, October 9, 2024

Clearside's Phase 2b Trial in Wet AMD Achieves Primary, Secondary Outcomes

In participants who received CLS-AX delivered suprachoroidally, BCVA and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept. 

Thursday, October 3, 2024

Harrow Relaunches Triesence

After 2 years unavailable in the US, the corticosteroid is once again on the market.

Thursday, October 3, 2024

Phase 3 Brepocitinib Trial Begins for Uveitis

FDA grants fast track designation for nonanterior noninfectious uveitis treatment.

Tuesday, September 24, 2024

Phase 2b SIGLEC Trial Enrollment Complete

The trial will compare intravitreal injection of AVD-104 to avacincaptad pegol for treatment of geographic atrophy secondary to age-related macular degeneration.

Monday, September 23, 2024

Bel-sar Shows Encouraging Results in Trial

In early-stage choroidal melanoma patients, suprachoroidal injection of bel-sar shows 80% tumor control and 90% vision preservation.

Monday, September 23, 2024

Gildeuretinol Acetate Reduces GA Lesion Growth

Data from the SAGA study showed patients with geographic atrophy showed improved visual acuity after 2 years on the oral therapy.

Thursday, September 19, 2024

Aflibercept Biosimilar Shows Equivalent Efficacy in DME Trial

MYL-1701P proves comparable to reference aflibercept at 52 weeks, according to data from the INSIGHT clinical trial.

Thursday, September 19, 2024

Dr. Andrea Govetto Receives First Ramin Tadayoni Award

The award, recognizing his innovative research in macular edema, was presented at the EURETINA meeting.

Wednesday, September 18, 2024

Atsena’s ATSN-201 Secures Orphan Drug Status

The FDA designation advances a potential gene therapy treatment for X-linked retinoschisis.

Wednesday, September 18, 2024

Opthea Validates Sozinibercept Manufacturing Process

Completion of PPQ campaign for novel wet AMD treatment strengthens path to regulatory approval

Friday, September 13, 2024

FDA Approves OCTA Capability on Robotic Camera

Topcon’s Maestro2 becomes the first robotic device available in the United States to offer OCT angiography.

Wednesday, September 11, 2024

Trial Indicates Ophthalmic Artery Angioplasty a Feasible Treatment for GA Lesions

The study demonstrated a positive safety profile and met secondary and exploratory endpoints associated with subjective and objective evidence of visual function preservation at 6 months.

Sunday, September 8, 2024

Study Finds ChatGPT-4 Useful for Uveitis Education

Information provided by the AI-driven platform compares favorably to traditional websites when it comes to patient education about uveitis.

Sunday, September 8, 2024

CNS Involvement in Vitreoretinal Lymphoma Explored

A recent study finds shorter survival in patients with concurrent CNS and vitreoretinal lymphoma.

Sunday, September 8, 2024

Melatonin May Lower AMD Risk

Study suggests that melatonin supplementation may reduce the risk of developing age-related macular degeneration.

Sunday, September 8, 2024

BRUNELLO Trial launched for DME Treatment

Restoret, a potential first-in-class therapy, to be tested for diabetic macular edema.

Sunday, September 8, 2024

BlueRock Receives FDA New Drug Clearance for OpCT-001 Cell Therapy

First iPSC-derived therapy for photoreceptor diseases to enter clinical testing.

Sunday, September 8, 2024

Promising LCA1 Gene Therapy Data Published

Phase 1/2 trial results show significant vision improvement for patients with Leber congenital amaurosis 12 months after therapy.

Friday, September 6, 2024

CMS Reports Potential Data Breach

Medicare beneficiaries may be affected by vulnerability in third-party software.

Friday, August 23, 2024

Low Hemoglobin Levels Linked to Retinopathy in Preterm Infants

Indian study finds increased risk for premature babies with low hemoglobin levels.

Tuesday, August 20, 2024

ASRS Launches PSAs to Prevent Vision Loss

Campaign highlights the importance of retina specialists in combating retinal diseases.

Tuesday, August 20, 2024

Opus Receives Gene Therapy Incentive from FDA

OPGx-LCA5 is currently being studied in clinical trial as a treatment for Leber congenital amaurosis.

Tuesday, August 20, 2024

Atsena Receives Gene Therapy Incentive from FDA

The company's ATSN-201 may provide hope for patients with X-linked retinoschisis.

Tuesday, August 20, 2024

Endophthalmitis Rates Drop 75% since 2000

Study reveals a significant decline in postoperative eye infection rates, likely due to improved treatment practices.

Tuesday, August 20, 2024

jCell Therapy Shows Promise in Restoring Vision

New study demonstrates potential for intravitreal retinal progenitor cell therapy in mitigating photoreceptor degeneration.

Tuesday, August 13, 2024

Annexon Begins Phase 3 Trial for GA Therapy

Monday, August 12, 2024

Eclipse Life Sciences Begins Phase 2 DME Trial

First patients dosed in clinical trial for novel corticosteroid implant.

Monday, August 12, 2024

New Biomarker Identified for Assessing DR Severity

Epiretinal macrophage–like cells could help monitor progression of diabetic retinopathy.

Monday, August 12, 2024

Mallinckrodt Launches Prefilled Injector

The new device, approved by the FDA earlier this year, delivers Acthar Gel, a uveitis treatment. 

Monday, August 12, 2024

Ocular Therapeutix Begins Phase 3 Wet AMD Trial

The SOL-R trial will evaluate the company's Axitinib implant as a treatment for wet age-related macular degeneration.

Monday, August 12, 2024

New Low-vision Wearable Device Unveiled

Eyedaptic's new Eye6 smart glasses utilize an AI assistant to help patients with daily tasks.

Monday, August 12, 2024

New CPT Code Approved for Photobiomodulation Therapy

The new code, which will go into effect next year, will facilitate reimbursement for PBM treatment in patients with dry AMD.

Monday, August 12, 2024

Aflibercept 8 mg Shows Broad Efficacy in DME Trial

Patients treated with Eylea HD showed significant gains in visual acuity, regardless of their baseline BCVA.

Tuesday, July 30, 2024

Macular Neovascularization in GA Patients Treated with ACP: GATHER Trials Analysis

Post hoc analysis reveals slightly increased MNV incidence with avacincaptad pegol 2 mg, but similar efficacy in geographic atrophy growth reduction regardless of MNV development.

Monday, July 29, 2024

AKT2 Identified as Potential Therapeutic Target for Dry AMD

Study reveals enzyme’s role in lysosome dysfunction and drusen formation in age-related macular degeneration.

Monday, July 29, 2024

Heidelberg Announces FDA Clearance of Faster OCTA Technology

The Spectralis OCTA module with SHIFT technology reduces acquisition time by 50% while maintaining high image quality.